New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)'s Push Into Immunology and Beyond

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbCellera Biologics Inc. stands amongst them.

AbCellera Biologics Inc. (NASDAQ:ABCL) is entering a new phase in 2025, shifting from discovery to clinical execution with multiple first-in-human trials now underway. In August, the company began Phase 1 studies for two AI-designed antibodies: ABCL575, targeting moderate-to-severe atopic dermatitis, and ABCL635, a first-in-class treatment for menopausal hot flashes. Both candidates leverage novel mechanisms, with ABCL575 showing strong safety and extended dosing potential, while ABCL635 offers a non-hormonal alternative for symptoms that remain underserved by current therapies.

Strengthening its leadership team, AbCellera Biologics Inc. (NASDAQ:ABCL) appointed Dr. Sarah Noonberg as Chief Medical Officer in September. Her expertise in clinical development is expected to accelerate regulatory progress and support the company’s expansion into new therapeutic areas, particularly immunological diseases.

The corporation’s momentum is reflected in its growing pipeline, which now includes 16 molecules in clinical development, alongside 97 initiated partner programs. This underscores robust demand for the business’s AI-powered antibody discovery platform, which combines advanced epitope mapping, microfluidics, and data-driven optimization to shorten the path from target identification to clinical trials.

Looking ahead, AbCellera Biologics Inc. (NASDAQ:ABCL) plans to launch additional clinical trials by the end of 2025, expand its integrated manufacturing capabilities, and continue scaling its AI platform.

While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.